Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.71859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 22.06.2026. Verfasst von Ben Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Jinzhou Medical University, Jinzhou, China. Hauptthemen laut MEDLINE: Immunotherapy, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Basic Scientific Research Project of Liaoning Provincial Department of Education in 2023.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The urothelial carcinoma (UC) trial landscape has expanded over two decades, alongside a shift from chemotherapy to immunotherapy and targeted approaches. We characterized temporal patterns in trial phase, interventions, sponsorship, geographic footprint, and the uptake of biomarker specification and artificial intelligence (AI) terminology.
Methods
We conducted a trial registry‐based analysis of 823 interventional UC studies first posted on ClinicalTrials.gov during 2005–2024. Trials were classified by phase, recruitment status, and intervention, and further stratified by sponsor type and geographic region. Registry text was mined to flag biomarker‐specified and AI‐enabled registrations. Trends were summarized overall and for two periods: 2005–2014 and 2015–2024.
Results
Annual registrations increased after 2015, peaking in 2018. Early‐phase studies predominated overall, with expansion of Phase 3 activity in 2015–2024. Drug interventions remained dominant as immunotherapy displaced chemotherapy; pembrolizumab was the leading agent in the later period. The sponsor mix shifted toward industry, and the geographic footprint broadened: the United States/Canada remained the largest contributor, with growth in multinational activity and increased participation from East Asia. Biomarker‐specified language rose to roughly one quarter of registrations in 2015–2024, whereas explicit AI terminology was rare. Early‐phase termination rates were notable.
Conclusions
UC trials have scaled and globalized while consolidating immunotherapy and advancing genomically directed strategies. Priorities include precise preregistration of biomarker and computational endpoints, inclusive multinational accrual, and adequately powered comparative trials against current standards to accelerate durable clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical College of Jinzhou Medical University, Jinzhou, China.
- Liaoning University of International Business and Economics, Dalian, China.
ORCID-Profile: Yihao Pei
Förderung
- the Basic Scientific Research Project of Liaoning Provincial Department of Education in 2023
Zitieren
APA
Li, B., Yang, Z., Pei, Y., Wang, Y., & Chen, Y. (2026). Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.71859
Vancouver
Li B, Yang Z, Pei Y, Wang Y, Chen Y. Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.71859
BibTeX
@article{Li2026,
author = {Li, Ben and Yang, Ziqi and Pei, Yihao and Wang, Yan and Chen, Yumin},
title = {Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.71859}
}
EUVIMED